Budget Impact of an Individualized Approach in the Treatment of HBeAg-Negative CHB Patients Exploiting the Week-12 Peginterferon Alfa-2a Stopping Rule in Italy

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.132

Related search